| Genomic classification and prognosis in acute myeloid leukemia E Papaemmanuil, M Gerstung, L Bullinger, VI Gaidzik, P Paschka, ... New England Journal of Medicine 374 (23), 2209-2221, 2016 | 4017 | 2016 |
| IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 … P Paschka, RF Schlenk, VI Gaidzik, M Habdank, J Kroenke, L Bullinger, ... Journal of clinical oncology 28 (22), 3636-3643, 2010 | 1007 | 2010 |
| Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study P Paschka, G Marcucci, AS Ruppert, K Mrózek, H Chen, RA Kittles, ... Journal of Clinical Oncology 24 (24), 3904-3911, 2006 | 854 | 2006 |
| Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular … K Mrózek, G Marcucci, P Paschka, SP Whitman, CD Bloomfield Blood 109 (2), 431-448, 2007 | 810 | 2007 |
| TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ... Blood, The Journal of the American Society of Hematology 119 (9), 2114-2121, 2012 | 707 | 2012 |
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ... Blood, The Journal of the American Society of Hematology 123 (21), 3247-3254, 2014 | 632 | 2014 |
| MicroRNA expression in cytogenetically normal acute myeloid leukemia G Marcucci, MD Radmacher, K Maharry, K Mrózek, AS Ruppert, ... New England Journal of Medicine 358 (18), 1919-1928, 2008 | 542 | 2008 |
| Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group J Krönke, RF Schlenk, KO Jensen, F Tschürtz, A Corbacioglu, VI Gaidzik, ... Journal of Clinical Oncology 29 (19), 2709-2716, 2011 | 485 | 2011 |
| An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia KH Metzeler, M Hummel, CD Bloomfield, K Spiekermann, J Braess, ... Blood, The Journal of the American Society of Hematology 112 (10), 4193-4201, 2008 | 454 | 2008 |
| Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation RF Schlenk, S Kayser, L Bullinger, G Kobbe, J Casper, M Ringhoffer, ... Blood, The Journal of the American Society of Hematology 124 (23), 3441-3449, 2014 | 448 | 2014 |
| Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and … H Becker, G Marcucci, K Maharry, MD Radmacher, K Mrózek, ... Journal of clinical oncology 28 (4), 596-604, 2010 | 432 | 2010 |
| RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group VI Gaidzik, L Bullinger, RF Schlenk, AS Zimmermann, J Röck, P Paschka, ... Journal of Clinical Oncology 29 (10), 1364-1372, 2011 | 398 | 2011 |
| Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia … G Marcucci, K Maharry, MD Radmacher, K Mrózek, T Vukosavljevic, ... Journal of clinical oncology 26 (31), 5078-5087, 2008 | 375 | 2008 |
| FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal … SP Whitman, AS Ruppert, MD Radmacher, K Mrózek, P Paschka, ... Blood, The Journal of the American Society of Hematology 111 (3), 1552-1559, 2008 | 358 | 2008 |
| Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study P Paschka, G Marcucci, AS Ruppert, SP Whitman, K Mrózek, K Maharry, ... Journal of Clinical Oncology 26 (28), 4595-4602, 2008 | 337 | 2008 |
| Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center: A 4.5‐year follow‐up T Lahaye, B Riehm, U Berger, P Paschka, MC Müller, S Kreil, K Merx, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 320 | 2005 |
| TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group VI Gaidzik, P Paschka, D Späth, M Habdank, CH Köhne, U Germing, ... Journal of clinical oncology 30 (12), 1350-1357, 2012 | 314 | 2012 |
| Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia J Krönke, L Bullinger, V Teleanu, F Tschürtz, VI Gaidzik, MWM Kühn, ... Blood, The Journal of the American Society of Hematology 122 (1), 100-108, 2013 | 313 | 2013 |
| RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features VI Gaidzik, V Teleanu, E Papaemmanuil, D Weber, P Paschka, J Hahn, ... Leukemia 30 (11), 2160-2168, 2016 | 310 | 2016 |
| Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia S Liu, LC Wu, J Pang, R Santhanam, S Schwind, YZ Wu, CJ Hickey, J Yu, ... Cancer cell 17 (4), 333-347, 2010 | 294 | 2010 |
richard schlenk在 nct-heidelberg.de 的电子邮件经过验证
